CN108778288A - 可用于治疗疾病的FimH的甘露糖衍生的拮抗剂 - Google Patents

可用于治疗疾病的FimH的甘露糖衍生的拮抗剂 Download PDF

Info

Publication number
CN108778288A
CN108778288A CN201780019049.3A CN201780019049A CN108778288A CN 108778288 A CN108778288 A CN 108778288A CN 201780019049 A CN201780019049 A CN 201780019049A CN 108778288 A CN108778288 A CN 108778288A
Authority
CN
China
Prior art keywords
mannopyranosyloxy
methyl
methylphenyl
compound
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780019049.3A
Other languages
English (en)
Chinese (zh)
Inventor
詹姆斯·W·简特卡
劳雷尔·麦多克-麦克格雷恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fei Mu Leon Medical Co
Original Assignee
Fei Mu Leon Medical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fei Mu Leon Medical Co filed Critical Fei Mu Leon Medical Co
Publication of CN108778288A publication Critical patent/CN108778288A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D75/00—Packages comprising articles or materials partially or wholly enclosed in strips, sheets, blanks, tubes or webs of flexible sheet material, e.g. in folded wrappers
    • B65D75/28—Articles or materials wholly enclosed in composite wrappers, i.e. wrappers formed by associating or interconnecting two or more sheets or blanks
    • B65D75/30—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding
    • B65D75/32—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents
    • B65D75/36—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents one sheet or blank being recessed and the other formed of relatively stiff flat sheet material, e.g. blister packages, the recess or recesses being preformed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mechanical Engineering (AREA)
  • Composite Materials (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780019049.3A 2016-03-23 2017-03-23 可用于治疗疾病的FimH的甘露糖衍生的拮抗剂 Pending CN108778288A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662312017P 2016-03-23 2016-03-23
US62/312,017 2016-03-23
PCT/US2017/023764 WO2017165619A1 (en) 2016-03-23 2017-03-23 Mannose-derived antagonists of fimh useful for treating disease

Publications (1)

Publication Number Publication Date
CN108778288A true CN108778288A (zh) 2018-11-09

Family

ID=59900869

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780019049.3A Pending CN108778288A (zh) 2016-03-23 2017-03-23 可用于治疗疾病的FimH的甘露糖衍生的拮抗剂

Country Status (10)

Country Link
US (3) US10738070B2 (enExample)
EP (1) EP3432892A4 (enExample)
JP (1) JP2019509315A (enExample)
KR (1) KR20180128937A (enExample)
CN (1) CN108778288A (enExample)
AU (1) AU2017238392A1 (enExample)
BR (1) BR112018069147A2 (enExample)
CA (1) CA3018345A1 (enExample)
RU (1) RU2018131440A (enExample)
WO (1) WO2017165619A1 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111205344A (zh) * 2020-01-14 2020-05-29 华东理工大学 一种用于甲醇溶剂识别的纯有机磷光小分子材料及其制备方法
CN111518738A (zh) * 2020-05-08 2020-08-11 徐州海润生物科技有限公司 重组卡介苗及其制备方法和应用
WO2021197363A1 (zh) * 2020-03-31 2021-10-07 苏州大学 2-炔基甘露糖衍生物及其应用
CN113795487A (zh) * 2019-05-07 2021-12-14 葛兰素史密斯克莱知识产权发展有限公司 新的化合物
CN113797212A (zh) * 2020-06-11 2021-12-17 兰州大学 一组含有甘露糖结构的抗菌药物的合成方法及活性研究
CN116621891A (zh) * 2023-05-25 2023-08-22 齐齐哈尔医学院 白鲜酚苷c及其制备方法和其应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018069147A2 (pt) 2016-03-23 2019-01-22 Fimbrion Therapeutics Inc composto da fórmula iii, composição farmacêutica, método de inibição da função de fimh e método de tratamento de uma doença mediada por fimh
US10385087B1 (en) * 2018-04-26 2019-08-20 National Taipei University Of Technology Xylose derivatives and process for preparation thereof
PL3820856T3 (pl) 2018-07-10 2022-12-19 Glaxosmithkline Intellectual Property Development Limited Związki c-mannozydów przydatne w leczeniu zakażeń układu moczowego
US12351597B2 (en) * 2019-06-19 2025-07-08 Glaxosmithkline Intellectual Property Development Limited Substituted biphenyl or phenylheteroaryl-mannosides as antagonists of FimH

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102753562A (zh) * 2009-12-14 2012-10-24 巴塞尔大学 作为细菌粘附拮抗剂的甘露糖衍生物
US20120309701A1 (en) * 2009-10-22 2012-12-06 The Washington University Compounds and methods for treating bacterial infections
US20140274930A1 (en) * 2013-03-12 2014-09-18 Vertex Pharmaceuticals Incorporated Mannose derivatives for treating bacterial infections
WO2014194270A1 (en) * 2013-05-30 2014-12-04 Washington University Compounds and methods for treating bacterial infections

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5122602A (en) 1989-02-13 1992-06-16 Miles Inc. Chromogenic merocyanine enzyme substrates
DK0730601T3 (da) 1993-11-18 2005-06-06 Univ Washington Forbindelser og farmaceutiske præparater til behandling af profylakse af bakterieinfektioner
US6420127B1 (en) 1994-11-18 2002-07-16 Washington University Compounds and pharmaceutical compositions for the treatment and prophylaxis of bacterial infections
WO2001010386A2 (en) 1999-08-11 2001-02-15 Washington University Anti-bacterial compounds directed against pilus biogenesis, adhesion and activity; co-crystals of pilus subunits and methods of use thereof
CA2411944C (en) 2000-06-09 2010-12-14 Baylor College Of Medicine The combination of antimicrobial agents and bacterial interference to coat medical devices
AU2003274127A1 (en) 2003-10-08 2005-04-21 Innovaprotean, S.L. Compounds for the treatment of diseases associated with the formation of amyloid fibrils
EP1755619A2 (en) 2004-03-23 2007-02-28 VIB vzw Anti-adhesive compounds to prevent and treat bacterial infections
SE528382C2 (sv) 2004-10-05 2006-10-31 Probi Ab Probiotiska lactobacillusstammar för förbättrad vaginal hälsa
FR2876798A1 (fr) 2004-10-14 2006-04-21 Univ Clermont Auvergne Diagnostic et traitement de la maladie de crohn
EP3492483A1 (en) 2009-10-22 2019-06-05 The Washington University Compounds and methods for treating bacterial infections
WO2012164074A1 (en) 2011-06-03 2012-12-06 University Of Basel Mannose phosphate derivatives as antagonists of bacterial adhesion
US20200002303A1 (en) 2016-03-11 2020-01-02 Fimbrion Therapeutics, Inc. C-glycoside compounds useful for treating disease
BR112018069147A2 (pt) 2016-03-23 2019-01-22 Fimbrion Therapeutics Inc composto da fórmula iii, composição farmacêutica, método de inibição da função de fimh e método de tratamento de uma doença mediada por fimh

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120309701A1 (en) * 2009-10-22 2012-12-06 The Washington University Compounds and methods for treating bacterial infections
CN102753562A (zh) * 2009-12-14 2012-10-24 巴塞尔大学 作为细菌粘附拮抗剂的甘露糖衍生物
US20140274930A1 (en) * 2013-03-12 2014-09-18 Vertex Pharmaceuticals Incorporated Mannose derivatives for treating bacterial infections
WO2014194270A1 (en) * 2013-05-30 2014-12-04 Washington University Compounds and methods for treating bacterial infections

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CASSIE JARVIS等: "Antivirulence Isoquinolone Mannosides: Optimization of the Biaryl Aglycone for FimH Lectin Binding Affinity and Efficacy in the Treatment of Chronic UTI", 《CHEMMEDCHEM》 *
LIJUAN PANG等: "FimH Antagonists: Structure–Activity and Structure-Property Relationships for Biphenyl α-D-Mannopyranosides", 《CHEMMEDCHEM》 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113795487A (zh) * 2019-05-07 2021-12-14 葛兰素史密斯克莱知识产权发展有限公司 新的化合物
CN111205344A (zh) * 2020-01-14 2020-05-29 华东理工大学 一种用于甲醇溶剂识别的纯有机磷光小分子材料及其制备方法
CN111205344B (zh) * 2020-01-14 2023-03-14 华东理工大学 一种用于甲醇溶剂识别的纯有机磷光小分子材料及其制备方法
WO2021197363A1 (zh) * 2020-03-31 2021-10-07 苏州大学 2-炔基甘露糖衍生物及其应用
US11964996B2 (en) 2020-03-31 2024-04-23 Jiyue Zheng 2-alkynylmannose derivative and application thereof
CN111518738A (zh) * 2020-05-08 2020-08-11 徐州海润生物科技有限公司 重组卡介苗及其制备方法和应用
CN113797212A (zh) * 2020-06-11 2021-12-17 兰州大学 一组含有甘露糖结构的抗菌药物的合成方法及活性研究
CN113797212B (zh) * 2020-06-11 2023-12-22 兰州大学 一组含有甘露糖结构的抗菌药物的合成方法及活性研究
CN116621891A (zh) * 2023-05-25 2023-08-22 齐齐哈尔医学院 白鲜酚苷c及其制备方法和其应用
CN116621891B (zh) * 2023-05-25 2023-10-31 齐齐哈尔医学院 白鲜酚苷c及其制备方法和其应用

Also Published As

Publication number Publication date
EP3432892A4 (en) 2019-10-30
US20250009723A1 (en) 2025-01-09
CA3018345A1 (en) 2017-09-28
RU2018131440A3 (enExample) 2020-05-18
AU2017238392A1 (en) 2018-09-27
US10738070B2 (en) 2020-08-11
US20200407390A1 (en) 2020-12-31
RU2018131440A (ru) 2020-04-23
KR20180128937A (ko) 2018-12-04
BR112018069147A2 (pt) 2019-01-22
WO2017165619A1 (en) 2017-09-28
US20190106451A1 (en) 2019-04-11
EP3432892A1 (en) 2019-01-30
JP2019509315A (ja) 2019-04-04

Similar Documents

Publication Publication Date Title
US20220235087A1 (en) Mannose-derived antagonists of fimh useful for treating disease
US20250009723A1 (en) Mannose-derived antagonists of fimh useful for treating disease
ES2895257T3 (es) Inhibidores de biciclo[1.1.1]pentano de cremallera de leucina doble cinasa (DLK) para el tratamiento de una enfermedad
KR102057877B1 (ko) 질소함유 헤테로고리 유도체 및 그의 약물에서의 용도
TW201910306A (zh) Nlrp3發炎體之選擇性抑制劑
CN108883122A (zh) 有用于治疗疾病的c-糖苷化合物
CN107074805B (zh) 用于治疗疾病的gls1抑制剂
AU2007288281A1 (en) Compounds and methods for inhibiting the interaction of Bcl proteins with binding partners
CN114430743A (zh) 甲状腺激素受体β激动剂化合物
JP6944442B2 (ja) 疾患を治療するためのｍｃｔ４阻害剤
JP7483820B2 (ja) 新規化合物
CN101790527A (zh) Rho激酶的苯并噻吩抑制剂
CN104606194A (zh) Pde4的双环杂芳基抑制剂
AU2014400628A1 (en) Aminopyridazinone compounds as protein kinase inhibitors
CN107921044B (zh) 用于治疗疾病的gls1抑制剂
JP2021519308A (ja) 転写活性化タンパク質のイミダゾピペラジン阻害剤
AU2019209475A1 (en) Inhibitors of cyclin-dependent kinase 7 (CDK7)
US11046649B2 (en) Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
WO2023143424A1 (zh) 一种氮杂并环衍生物及其在医药上的应用
WO2023141852A1 (zh) Cdk2抑制剂及其制备方法和用途
CN114980886B (zh) 用于治疗草酸盐相关疾病的化合物和方法
CN117003754A (zh) 吡咯并[2,3-d]嘧啶或吡唑并[3,4-d]嘧啶衍生物及其用途
JP7628506B2 (ja) 新規化合物
HK40037519B (zh) Ptpn11的取代的杂环抑制剂
WO2021136326A1 (zh) 芳香酰胺类化合物及其在药物中的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20181109

WD01 Invention patent application deemed withdrawn after publication